Alongside conventional therapies, CFTR modulators (e.g., lumacaftor-ivacaftor) represent an important advance in management of CF, as instead of treating the consequences of the CFTR dysfunction, they target the production or function of the mutant CFTR protein, with the potential of dramatically changing the natural history of this disease [11,12]. The gene discussed is CFTR; the disease is cystic fibrosis.